Not all is perfect with Tenofovir alafenamide
Authors:
- 29 December 2019
- journal article
- letter
- Published by Wiley in HIV Medicine
- Vol. 21 (6) , E10-E11
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studiesThe Lancet HIV, 2019
- Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIVNew England Journal of Medicine, 2019
- HIV infection and coronary heart disease: mechanisms and managementNature Reviews Cardiology, 2019
- Planning HIV therapy to prevent future comorbidities: patient years for tenofovir alafenamideHIV Medicine, 2019
- Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trialsThe Lancet, 2019
- A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015–2017Infection, 2018
- Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 TrialClinical Infectious Diseases, 2017
- Bone mineral density and inflammatory and bone biomarkers after darunavir–ritonavir combined with either raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trialThe Lancet HIV, 2015